Home › Trials › NCT05219851
Clinical trial No longer in our active list Observational

Identifying risk factors for lung complications in cancer patients treated with immunotherapy and radiation

Official title: The Risk Factors for Acute Radiation Pneumonitis in Patients With Prior Receipt of Immune Checkpoint Inhibitors.in Real-world Clinical Practice: a Multicenter, Prospective, Open, Non-interventional Study

Run by Hubei Cancer Hospital · NCT05219851 · Data updated 2026-05-14

This study is no longer in our active list. It may have stopped recruiting or finished. The details below are as of 2026-05-14 and are kept for reference. Check ClinicalTrials.gov for its current status, or see similar studies below.

This study looks at cancer patients who have had immunotherapy and radiation to see what factors might increase their risk of developing lung complications.

More Rectal Cancer Patients trials

Quick facts

Study typeObservational
SexAll
Enrollment250 (estimated)
SponsorHubei Cancer Hospital
Academic / other
Drugs / interventionsimmunotherapy, radiation
Locations1 site (Wuhan, Hubei)
Trial IDNCT05219851 on ClinicalTrials.gov

Is this trial a fit for you?

Likely a good fit

Ideal candidates include cancer patients with confirmed malignant tumors who have previously received immune checkpoint inhibitors and are scheduled for thoracic radiotherapy.

Probably not a fit

Patients who have not received immunotherapy prior to thoracic radiotherapy or those undergoing non-thoracic radiotherapy may not benefit from this study.

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

This observational study aims to gather data on the incidence of acute radiation pneumonitis (aRPs) in cancer patients who have previously received immune checkpoint inhibitors (ICIs) and subsequently underwent thoracic intensity-modulated radiotherapy. The study will analyze various risk factors, particularly dosimetric factors, that may contribute to the development of aRPs. Additionally, it seeks to establish a predictive model to guide clinical treatment decisions for affected patients.

Why it matters

Potential benefit: If successful, this study could help identify at-risk patients and improve management strategies for those undergoing radiotherapy after immunotherapy.

How similar studies have gone: While there is ongoing research into the effects of immunotherapy and radiotherapy, this specific focus on acute radiation pneumonitis in this patient population is relatively novel.

Who can join: the full rules

Show full inclusion / exclusion criteria 
Inclusion Criteria:

1. Pathologically or cytologically confirmed malignant tumor
2. Cancer patients with previously received ICIs underwent thoracic intensity-modulated radiotherapy

Exclusion Criteria:

1. Cancer patients did not receive immunotherapy before thoracic intensity-modulated radiotherapy
2. Non-thoracic radiotherapy patients

Where it's running

  • Hubei Cancer Hospital
    Wuhan, Hubei, China     Recruiting

Study contacts

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

How to take part

  1. Review the eligibility criteria above with your treating physician.
  2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
  3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.
View on ClinicalTrials.gov ↗ Find more trials like this →
Browse more
Cancer Patients 8Hubei Cancer Hospital 12
Last reviewed 2026-11-14 by the Find a Trial editorial team. Information on this page is for educational purposes and is not medical advice. Always consult qualified healthcare professionals about clinical trial participation.